Rolph Timothy

CSO Rolph Timothy sells 37,500 AKRO shares for $2,044,633.55 (blended $54.52); 5 of 5 prior AKRO sells proved well-timed with negative 90-day returns.

Rolph Timothy, Chief Scientific Officer, executed 3 separate sales totaling 37,500 shares for $2,044,633.55 on June 5–6, 2025, reducing his holdings by 18.1% from 207,221 to 169,721 shares. This filing adds to a distinct pattern: all 5 of his prior trades at AKRO were sells, and each proved well-timed at the 90-day mark with negative returns ranging from -25.4% to -28.0%, meaning the stock declined after each prior sale. His cross-ticker track record shows an identical 100.00% well-timed rate on 8 prior sells. Against this backdrop, the company remains unprofitable (net income $-70,725,000.00 over the most recent full fiscal year), and the stock has risen 37.3% in the past 30 days and 24.8% in 90 days—positioning this sale near a 52-week high ($55.04 transaction price vs. $57.56 high). The consistency of well-timed sales at this ticker, combined with the recent sharp appreciation, suggests the insider perceived a tactical exit point.

CSO Rolph Timothy sold 18,750 shares (18.8K) at blended $56.51 for $1,059,629.65 ($1.1M) on 2025-02-05.

Rolph Timothy, Chief Scientific Officer at Akero Therapeutics, executed 2 separate sales totaling 18,750 shares for $1,059,629.65 on 2025-02-05. The sales reduced his holdings by 9.9%, from 188,987 shares to 170,237 shares. The transaction prices ($56.32 and $56.92, blended $56.51) were substantially above the current price of $54.21, and near the 52-week high of $57.56, despite the stock being up 107.2% in the past 30 days and 57.4% in the past 90 days. The company remains unprofitable with negative net income of $-72,705,000.00 for its most recent full fiscal year. Timothy's cross-ticker track record shows a 100.00% well-timed rate on prior sells, with negative average 90-day returns of -8.3%, though his prior sales at AKRO (on 2023-06-16) were also well-timed with 90-day declines of -7.0% and -7.9% respectively.

CSO Rolph Timothy sells 31,250 shares at $55.77 avg for $1.7M as AKRO hits 52-week high

Rolph Timothy, Chief Scientific Officer, executed 3 separate sales totaling 31,250 shares for $1,742,958.33 on 2025-01-27 at prices ranging from $54.76 to $56.97, representing a 15.5% reduction in his 201,487-share holdings. The sale occurred at the peak of AKRO's 52-week range ($54.00 current price at 52-week high of $54.00), following a dramatic 93.1% surge in the prior 30 days and 75.2% appreciation over 90 days. His cross-ticker track record shows 3 prior open-market sells with a 100.00% well-timed rate at the 90-day mark (average 90d return of -8.3%), and his same-ticker history at AKRO shows all 3 prior sales were well-timed. However, the company remains unprofitable with a net loss of $72.7M, limiting the interpretive weight of valuation-based rationales. The sale's execution at market peaks in conjunction with his demonstrated historical pattern of selling before subsequent declines warrants monitoring of near-term price action to contextualize this transaction's implications.